

### Amendments To the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

Claims 1-7 (canceled)

8. (currently amended) The compound of Claim 23 wherein R<sup>2</sup> is selected from:

- (1) -CH<sub>2</sub>-(phenyl),
- (2) -CH<sub>2</sub>-(4-bromophenyl),
- (3) -CH<sub>2</sub>-(3-chlorophenyl),
- (4) -CH<sub>2</sub>-(3,5-difluorophenyl),
- (5) -CH<sub>2</sub>-((2-trifluoromethyl)phenyl),
- (6) -CH<sub>2</sub>-((3-trifluoromethyl)phenyl),
- (7) -CH<sub>2</sub>-((4-trifluoromethyl)phenyl),
- (8) -CH<sub>2</sub>-((3-trifluoromethoxy)phenyl),
- (9) ~~-CH<sub>2</sub>-((3-trifluoromethylthio)phenyl),~~
- (10) ~~-CH<sub>2</sub>-((3-trifluoromethoxy-5-thiomethyl)phenyl),~~
- (11) (9) -CH<sub>2</sub>-((3-trifluoromethoxy-5-methoxy)phenyl),
- (12) ~~-CH<sub>2</sub>-((3-trifluoromethoxy-5-methanesulfonyl)phenyl),~~
- (13) ~~-CH<sub>2</sub>-((3-trifluoromethoxy-5-amino)phenyl),~~
- (14) ~~-CH<sub>2</sub>-((3-trifluoromethoxy-5-aminomethanesulfonyl)phenyl),~~
- (15) ~~-CH<sub>2</sub>-((3-trifluoromethoxy-5-sulfonylamino)phenyl),~~
- (16) (10) -CH<sub>2</sub>-((3,5-bis-trifluoromethyl)phenyl),
- (17) (11) -CH<sub>2</sub>-((3-fluoro-5-trifluoromethyl)phenyl),
- (18) (12) -CH(CH<sub>3</sub>)-((3,5-bis-trifluoromethyl)phenyl), and
- (19) (13) -C(CH<sub>3</sub>)<sub>2</sub>-((3,5-bis-trifluoromethyl)phenyl);
- (20) ~~-CH<sub>2</sub>-(4-(2-trifluoromethyl)pyridyl),~~
- (21) ~~-CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridyl),~~
- (22) ~~-CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridazinyl),~~
- (23) ~~-CH<sub>2</sub>-(4-(2-trifluoromethyl)pyridyl N-oxide), and~~
- (24) ~~-CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridyl N-oxide).~~

9. (previously presented) The compound of Claim 23 wherein R<sup>3</sup> is heterocycle, where the heterocycle is selected from: imidazole, pyrimidyl, triazole and tetrazole,


where the heterocycle is unsubstituted or substituted with 1-5 substituents as defined in Claim 23.

10. (previously presented) The compound of Claim 23 wherein R<sup>3</sup> is heterocycle,  
where the heterocycle is unsubstituted or substituted with 1-3 substituents independently selected from:

- (a) halo,
- (c) hydroxy,
- (d) C<sub>1-3</sub>alkyl,
- (e) -O-C<sub>1-3</sub>alkyl, and
- (f) -CO<sub>2</sub>R<sup>9</sup>.

11. (previously presented) The compound of Claim 23 wherein R<sup>3</sup> is selected from: imidazole, pyrimidyl, triazole and tetrazole.

12. (previously presented) The compound of Claim 23 wherein R<sup>3</sup> is selected from:



Claims 13-17 (canceled)

18. (previously presented) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 23.


19. (withdrawn) A method for modulation of chemokine receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 1- 23.

20. (withdrawn) A method for treating, ameliorating or controlling an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1- 23.

21. (withdrawn) A method for reducing the risk of an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1- 23.

22. (withdrawn) A method for treating, ameliorating or controlling rheumatoid arthritis which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1- 23.

23. (currently amended) A compound of the formula I:



wherein:

R<sup>1</sup> is selected from the group consisting of:

(1) -CH(CH<sub>3</sub>)<sub>2</sub> and

(2) -C(CH<sub>3</sub>)<sub>2</sub>(OH);

(1) —CH<sub>3</sub>;

(2) —CH<sub>2</sub>CH<sub>3</sub>;

(3) —CH(CH<sub>3</sub>)<sub>2</sub>;

(4) —CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

(5) —CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>;

- (6) — cyclopropyl,
- (7) — cyclobutyl,
- (8) — cyclopentyl,
- (9) — CH<sub>2</sub>-cyclopropyl,
- (10) — CH<sub>2</sub>-cyclobutyl,
- (11) — CH<sub>2</sub>-cyclopentyl,
- (12) — CH<sub>2</sub>OH,
- (13) — C(CH<sub>3</sub>)<sub>2</sub>(OH),
- (14) — C(CH<sub>2</sub>OH)(CH<sub>3</sub>)<sub>2</sub>,
- (15) — (OH)cyclobutyl,
- (16) — (OH)cyclopentyl,
- (17) — C(CH<sub>3</sub>)<sub>2</sub>(NHCOCH<sub>3</sub>),
- (18) — C(CO<sub>2</sub>H)(CH<sub>3</sub>)<sub>2</sub>,
- (19) — O-CH<sub>3</sub>,
- (20) — O-cyclopentyl,
- (21) — O-CH(CH<sub>3</sub>)<sub>2</sub>,
- (22) — S-CH<sub>3</sub>,
- (23) — S-CF<sub>3</sub>,
- (24) — SO<sub>2</sub>-CH<sub>3</sub>,
- (25) — S-CH(CH<sub>3</sub>)<sub>2</sub>,
- (26) — SO<sub>2</sub>-CH(CH<sub>3</sub>)<sub>2</sub>, and
- (27) — NH-SO<sub>2</sub>-CH<sub>3</sub>;

R<sup>2</sup> is selected from the group consisting of -CH<sub>2</sub>-phenyl, -CH(CH<sub>3</sub>)-phenyl, and -C(CH<sub>3</sub>)<sub>2</sub>-phenyl, wherein phenyl is unsubstituted or substituted with 1-3 substituents independently selected from:

- (a) halo,
- (b) trifluoromethyl,
- (c) trifluoromethoxy,
- (d) hydroxy,
- (e) C<sub>1-3</sub>alkyl,
- (f) -O-C<sub>1-3</sub>alkyl, and
- (g) -CO<sub>2</sub>H;
- (g) — CO<sub>2</sub>-C<sub>1-3</sub>alkyl,
- (h) — CO<sub>2</sub>H,
- (i) — S-C<sub>1-3</sub>alkyl,

- (j) —SO<sub>2</sub>-C<sub>1-3</sub>alkyl;
- (k) —SCF<sub>3</sub>;
- (l) —NH<sub>2</sub>;
- (m) —NH-SO<sub>2</sub>-C<sub>1-3</sub>alkyl, and
- (n) —SO<sub>2</sub>-NH<sub>2</sub>;

R<sup>3</sup> is a heterocycle, wherein the heterocycle is selected from the group consisting of benzoimidazolyl, ~~benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazoliny, quinolyl, quinoxaliny, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and imidazolidinone; azetidiny, 1,4-dioxany, hexahydroazepiny, piperaziny, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinoliny, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidiny, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof,~~

wherein the heterocycle is unsubstituted or substituted with 1-5 substituents independently selected from:

- (a) halo,
- (b) trifluoromethyl,
- (c) hydroxy,
- (d) C<sub>1-3</sub>alkyl,
- (e) -O-C<sub>1-3</sub>alkyl,
- (f) -CO<sub>2</sub>R<sup>9</sup>,
- (g) -CN,
- (h) -NR<sup>9</sup>R<sup>10</sup>, and
- (i) -CONR<sup>9</sup>R<sup>10</sup>;

R<sup>4</sup>, R<sup>6</sup>, R<sup>9</sup> and R<sup>10</sup> are H;

R<sup>5</sup> is selected from:

- (a) hydrogen,
- (b) -CH<sub>3</sub>, and
- (c) -O-CH<sub>3</sub>; and

n is the integer 1; or

a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.

24. (previously presented) The compound of Claim 23 which is selected from the group consisting of the compounds below, or a pharmaceutically acceptable salt or individual diastereomer thereof:

